Skye Bioscience, Common Morgan Bond
| SKYE Stock | USD 2.46 0.20 7.52% |
Skye Bioscience, Common holds a debt-to-equity ratio of 0.836. At present, Skye Bioscience,'s Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.42, whereas Short and Long Term Debt Total is forecasted to decline to about 2.8 M. . Skye Bioscience,'s financial risk is the risk to Skye Bioscience, stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Skye Bioscience,'s liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Skye Bioscience,'s cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Skye Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Skye Bioscience,'s stakeholders.
For most companies, including Skye Bioscience,, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Skye Bioscience, Common, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Skye Bioscience,'s management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.9846 | Book Value 2.499 | Return On Assets (0.30) | Return On Equity (0.55) |
Skye |
Given the importance of Skye Bioscience,'s capital structure, the first step in the capital decision process is for the management of Skye Bioscience, to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Skye Bioscience, Common to issue bonds at a reasonable cost.
| Popular Name | Skye Bioscience, Morgan Stanley 3591 |
| Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
| Equity ISIN Code | US83086J1016 |
| Bond Issue ISIN Code | US61744YAK47 |
| S&P Rating | Others |
| Maturity Date | 22nd of July 2028 |
| Issuance Date | 24th of July 2017 |
| Coupon | 3.591 % |
Skye Bioscience, Common Outstanding Bond Obligations
| Dana 575 percent | US235822AB96 | Details | |
| Boeing Co 2196 | US097023DG73 | Details | |
| MPLX LP 4875 | US55336VAG59 | Details | |
| MPLX LP 4125 | US55336VAK61 | Details | |
| MPLX LP 52 | US55336VAL45 | Details | |
| SWKS 3 01 JUN 31 | US83088MAL63 | Details | |
| SWKS 18 01 JUN 26 | US83088MAK80 | Details | |
| US830867AB33 | US830867AB33 | Details | |
| US830867AA59 | US830867AA59 | Details | |
| Morgan Stanley 3591 | US61744YAK47 | Details | |
| Morgan Stanley 3971 | US61744YAL20 | Details |
Understaning Skye Bioscience, Use of Financial Leverage
Skye Bioscience,'s financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Skye Bioscience,'s total debt position, including all outstanding debt obligations, and compares it with Skye Bioscience,'s equity. Financial leverage can amplify the potential profits to Skye Bioscience,'s owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Skye Bioscience, is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt | 4.4 M | 4.6 M | |
| Long Term Debt | 1.6 M | 1.2 M | |
| Short and Long Term Debt Total | 4.6 M | 2.8 M | |
| Net Debt | 3.4 M | 3.5 M | |
| Short Term Debt | 4.4 M | 2.3 M | |
| Net Debt To EBITDA | (0.25) | (0.26) | |
| Debt To Equity | (2.05) | (1.95) | |
| Interest Debt Per Share | 0.75 | 0.72 | |
| Debt To Assets | 0.37 | 0.42 | |
| Long Term Debt To Capitalization | 0.68 | 0.72 | |
| Total Debt To Capitalization | 1.95 | 2.05 | |
| Debt Equity Ratio | (2.05) | (1.95) | |
| Debt Ratio | 0.37 | 0.42 | |
| Cash Flow To Debt Ratio | (3.19) | (3.35) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out the analysis of Skye Bioscience, Fundamentals Over Time. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.